Jose M. Rubio, MD, PhD
a:3:{i:0;s:71:"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York";i:1;s:94:"Institute of Behavioral Science, Feinstein Institutes of Medical Research, Manhasset, New York";i:2;s:41:"Northwell Health, New Hyde Park, New York";}
ASCP Corner
Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians
May 5, 2025
While the abolition of REMS for clozapine expands access, the change could create confusion. Among the most relevant examples are mismatches between FDA recommendations for lifetime monitoring and the...
Review Article
Outcomes of NMS With Depot Versus Oral Antipsychotics
November 24, 2020
Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
ASCP Corner
Nonpsychotic Psychiatric Disorders and Substance Use Disorders
April 26, 2017
This month's ASCP Corner discusses the significant problem of untreated psychiatric disorders and substance use disorders. The authors review the association between untreated illness and morbidity/mortality, look at ways...
ASCP Corner
Duration and Relevance of Untreated Psychiatric Disorders, 1: Psychotic Disorders
March 29, 2017
This month's ASCP Corner discusses the significant problem of untreated psychosis. The authors review the factors that contribute to a longer time to treatment, the impact of untreated psychosis,...
